Efficacy and safety of 3-month versus 6-month oxaliplatin-based adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis.

Front Oncol · 2026 · PMC12907182 · PMID 41704616

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Among stage III patients, both DFS and the 3-year DFS rate were slightly lower in the 3-month group compared with the 6-month group; however, the differences did not reach statistical significance.

also in 111,027 other papers

highly significantno p-value reported

Our findings further revealed that the incidences of grade 2 and grade 3–4 PSN were all significantly lower in the 3-month regimen than in the 6-month regimen, with severe (grade 3–4) PSN occurring in only 4.2% of patients receiving 3 months of therapy compared with 13.6% in those receiving 6 months— a highly significant difference.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.